Related Experiment Video
Updated: Aug 16, 2026
07:39
Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion
Published on: June 29, 2012
Drug-metabolizing enzymes in rat liver myofibroblasts
1Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Biochemical Pharmacology
|March 27, 1998
Summary
Hepatic fibrosis treatment is limited. Myofibroblasts, key in fibrosis, possess drug-metabolizing enzymes, suggesting a role in pentoxifylline
Area of Science:
- Pharmacology
- Hepatology
- Cell Biology
Background:
- Hepatic fibrosis pathogenesis involves myofibroblasts, yet effective anti-fibrotic therapies are scarce.
- Current treatments offer limited efficacy, primarily managing liver enzymes without preventing fibrosis progression.
- Pentoxifylline demonstrates anti-fibrotic effects, with its metabolites M-1 and M-1R showing therapeutic potential.
Purpose of the Study:
- To investigate if myofibroblasts, crucial in hepatic fibrosis, possess drug-metabolizing enzymes.
- To determine the role of these enzymes in the anti-fibrotic actions of pentoxifylline.
- To explore the potential link between myofibroblast drug metabolism and pentoxifylline's efficacy.
Main Methods:
- Assessing drug-metabolizing enzyme activities within isolated myofibroblasts.
- Measuring aryl hydrocarbon hydroxylase, ethoxyresorufin O-deethylase, and methoxyresorufin O-demethylase activities.
- Evaluating the impact of dibenzanthracene, a CYP1A inducer, on these enzyme activities.
Main Results:
- Myofibroblasts exhibit significant aryl hydrocarbon hydroxylase, ethoxyresorufin O-deethylase, and methoxyresorufin O-demethylase activities.
- Dibenzanthracene treatment increased aryl hydrocarbon hydroxylase and methoxyresorufin O-demethylase activities in myofibroblasts.
- These findings indicate myofibroblasts possess functional drug-metabolizing enzymes, particularly CYP1A-related activities.
Conclusions:
- Myofibroblasts contain drug-metabolizing enzymes, suggesting they play a direct role in pentoxifylline metabolism.
- This intrinsic metabolic capacity may be critical for pentoxifylline's anti-fibrotic effects.
- Targeting myofibroblast drug metabolism could offer novel therapeutic strategies for hepatic fibrosis.
Related Concept Videos
01:16Drug Biotransformation: Overview
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...